CWM
ALXN

Calamos Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Calamos Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,258
Closed -$562K – 271
2020
Q1 		$562K Sell
6,258
-22,574
-78% -$2.22M 0.09% 142
2019
Q4 		$3.12M Buy
28,832
+241
+0.8% +$25.8K 0.37% 70
2019
Q3 		$2.8M Buy
28,591
+498
+2% +$56.1K 0.37% 74
2019
Q2 		$3.68M Buy
28,093
+583
+2% +$75.1K 0.5% 57
2019
Q1 		$3.72M Buy
27,510
+4,834
+21% +$601K 0.53% 56
2018
Q4 		$2.21M Buy
+22,676
New +$2.68M 0.33% 70
2016
Q4 		– Sell
-5,695
Closed -$698K – 235
2016
Q3 		$698K Sell
5,695
-6,658
-54% -$857K 0.12% 166
2016
Q2 		$1.44M Sell
12,353
-490
-4% -$69.5K 0.25% 132
2016
Q1 		$1.79M Buy
12,843
+907
+8% +$133K 0.34% 96
2015
Q4 		$2.28M Buy
11,936
+5,651
+90% +$987K 0.45% 63
2015
Q3 		$983K Buy
6,285
+3,813
+154% +$696K 0.24% 142
2015
Q2 		$447K Buy
+2,472
New +$427K 0.11% 184

Other funds holding ALXN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Calamos Wealth Management's ALXN Position: Q2 2020 in Review

Calamos Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 6,258 shares — an estimated $562K sold.

Calamos Wealth Management first reported a position in ALXN in Q2 2015 and held it in 12 quarters. The position peaked at $3.72M in Q1 2019. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • Calamos Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Calamos Wealth Management sold 6,258 Alexion Pharmaceuticals shares in Q2 2020, an estimated $562K.
  • Calamos Wealth Management first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 12 quarters.
  • Calamos Wealth Management's Alexion Pharmaceuticals position peaked at $3.72M in Q1 2019.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on Calamos Wealth Management's 13F filing for Q2 2020, filed 27 Jul 2020.